In recent decades the scientific world has entered a new era of drug discovery, in which it became possible to discover and develop unique small molecules and proteins targeting various oncological diseases. This was made feasible thanks to advances in molecular and cell biology which speeded up the drug discovery process at the preclinical stage. Recent innovations in anticancer therapies, including small molecules, peptide drugs, monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, and CAR-T cell applications, led scientists into a whole new chapter in cancer research.
Selvita scientists are constantly improving research strategies to support our clients in the discovery of efficient and safe pharmaceuticals. Our teams of biochemists and in vitro biologists have broad expertise in working with both small-molecular weight NCEs, as well as peptide and protein anticancer drugs.
We can assist with the development and execution of multiple assays, depending on MoA and characteristics of the anticancer medicine under development:
- Cytotoxicity/proliferation assays (cell lines, 2D and spheroids)
- Cell cycle arrest and apoptosis assays
- Biomarkers in vitro and in vivo
- Angiogenesis assays
- Migration and invasion assays
- Assays measuring immune checkpoint inhibitor pathways activity
- ADCC and CDC assays
- mAbs assays (neutralization assays, Fab-associated function assays)
- Cytokine profiling (including multiplexing)
- Gene expression
- Battery of phenotypic assays/screening with the use of HCS
- Flow cytometry analysis
In our research, we use primary cells (PBMC, NKs, T-cells, innate immunity cells), multiple cancer cell lines, iPS-derived cells, and co-cultures. If needed, recombinant cell lines are generated by our team specialized in genetic engineering.
Assay cascades developed by our scientists include assays for on-target and off-target activity determination and are supported by primary biophysical and biochemical assays in standard and HTS format.